EntreMed’s senior management team reports to the Executive Committee and is responsible for aligning the company’s business strategy with its core scientific strengths, while maintaining prudent resource management, fiscal responsibility and accountability. The team has redirected EntreMed’s financial resources and R&D strategy to focus on the development of its Aurora A and angiogenic kinase inhibitor, ENMD-2076.

Cynthia W. Hu, JD. Ms. Hu joined EntreMed in June 2006 as Vice President, General Counsel & Secretary and was appointed Chief Operating Officer in December 2008. Prior to joining EntreMed, from January 2000 to May 2006, Ms. Hu served as senior attorney for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu served as counsel for ING Annuities (formerly Golden American Life Insurance Company) and an attorney with the law firms of Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on corporate transactions and compliance with corporate and securities laws.

Carolyn F. Sidor, MD. Dr. Sidor joined EntreMed in 2001 as Vice President, Clinical & Regulatory Affairs and was appointed Chief Medical Officer in September 2004. Dr. Sidor is a board-certified hematologist/medical oncologist. Prior to joining EntreMed, Dr. Sidor held various leadership positions at Cato Research Ltd., a prominent Clinical Research Organization (CRO), including Vice President, Scientific and Medical Development; Medical Director; Senior Clinical Research Physician; and Project Director.

Kathy R. Wehmeir-Davis. Ms. Wehmeir-Davis joined EntreMed in November 2003 as the company’s Controller and was appointed Principal Accounting Officer in December 2008. She is responsible for managing the financial accounting operations of the Company and ensuring the Company’s compliance with the internal control requirements of the Sarbanes-Oxley Act of 2002. Prior to joining EntreMed, from 2000 to 2003, Ms. Wehmeir-Davis served as Senior Accountant for Avemco Insurance Company of Frederick, MD, a subsidiary of HCC Insurance Holdings, Inc. Ms. Wehmeir-Davis’ career began in public accounting, serving 15 years with McLean, Koehler, Sparks & Hammond, CPAs, as Senior Accountant and Auditor.

Mark R. Bray, PhD. Dr. Bray joined EntreMed in January 2006 as Senior Director, Research and in November 2007, Dr. Bray was promoted to Vice President, Research. Dr. Bray has spent his scientific career working towards the development of drugs for oncology and inflammatory diseases. Dr. Bray joined EntreMed in 2006 following the acquisition of Miikana Therapeutics, Inc., a biopharmaceutical company co-founded by Dr. Bray and others, which was focused on the development of targeted therapeutics for the treatment of cancer. Prior to the founding of Miikana in November 2002, Dr. Bray was Head of Quantitative Biology at the Amgen Research Institute in Toronto, Canada, and acted as Project Team Leader for multiple drug discovery efforts at Amgen, Thousand Oaks, CA.